SHR 0302Alternative Names: SHR0302
Latest Information Update: 10 Jan 2018
Price : *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Janus kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 05 Jan 2018 SHR 0302 licensed to Arcutis in USA, European Union and Japan
- 05 Jan 2018 Phase-II clinical trials in Rheumatoid arthritis (In adults, In the elderly, Treatment-experienced) in China (PO) (NCT03254966)
- 23 Aug 2017 Jiangsu HengRui Medicine plans a phase II trial for Rheumatoid arthritis (Monotherapy) in China (NCT03254966)